

the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

REC
SECRETARY
PUBLIC

05 FEB 17

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The OB-C Group, LLC			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1350 Eye Street, NW Suite 690 City Washington State/Zip (or Country) DC 20005 USA			
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)			
4. Contact Name Celeste Dembowski	Telephone 202-898-4746	E-mail (optional) cdembowski@ob-cgroup.com	5. Senate ID # 29802-366
7. Client Name <input type="checkbox"/> Self Biotechnology Industry Organization			6. House ID # 30108032

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____ 11. No Lobbyin

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >>\$ <u>\$160,000.00</u> <small>Income (nearest \$20,000)</small> Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >>\$ _____ <small>Expenses (nearest \$20,000)</small> 14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033 of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator _____ Pag

Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ACC (one per page)

16. Specific Lobbying issues

H.R.1372 , Broad-Based Stock Option Plan Transparency Act of 2003, entire bill.

H.R.286, To amend the Internal Revenue Code of 1986 to clarify the treatment of incentive stock options and stock purchase plans, entire bill.

H.R.3574, Stock Option Accounting Reform Act, entire bill.

H.R.4520, American Jobs Creation Act of 2004, entire bill.

H.RES.725, Providing for consideration of the bill (H.R. 3574) to require the mandatory expensing of stock options, entire bill.

S.1890, Stock Option Accounting Reform Act, entire bill.

S.206, A bill to amend the Internal Revenue Code of 1986 to clarify the treatment of incentive stock options and stock purchase plans, entire bill.

S.979 , Broad-Based Stock Option Plan Transparency Act of 2003, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Printed Name and Title Celeste Dembowski - Office Administrator Page

Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues

***, no specific bill, proposed policy re: adventitious presence.

H.R.4454, Ecoterrorism Prevention Act of 2004, entire bill.

H.R.4766, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2005, entire bill.

S.2803, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2005, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Pa

Client Name: **Biotechnology Industry Organization**

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.R.1561, United States Patent and Trademark Fee Modernization Act of 2003, PTO fee.

H.R.2537, Emergency Warning Act of 2003, security issues.

H.R.4567, Department of Homeland Security Appropriations Act, 2005, Homeland Security issues.

H.R.4568, Department of the Interior and Related Agencies Appropriations Act, 2005, Interior-related issues.

H.R.4613, Department of Defense Appropriations Act, 2005, Defense issues.

H.R.4614, Energy and Water Development Appropriations Act, 2005, Energy and water issues.

H.R.4754, Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Commerce, Justice and State Department Appropriations issues.

H.R.4755, Legislative Branch Appropriations Act, 2005, entire bill.

H.R.4766, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations 2005, Agriculture Appropriations issues.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Page _____

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
16	Lobbying Issues	H.R.4818, Foreign Operations, Export Financing, and Related Programs Appropriations Act, 2005, Omnibus / Supplemental Appropriations issues.
16	Lobbying Issues	S.2559, Department of Defense Appropriations Act, 2005, Defense issues.
16	Lobbying Issues	S.2606, A bill to amend the Federal Water Pollution Control Act to reauthorize National Estuary Program, water pollution issues.
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

H.R.1561 , United States Patent and Trademark Fee Modernization Act of 2003, entire bill.

H.R.2391 , Cooperative Research and Technology Enhancement (CREATE) Act of 2003, entire bill.

H.R.5117, Fortifying America's Intellectual Property Rights (FAIR) Act, entire bill.

H.R.5299, Patent Quality Assistance Act of 2004, entire bill.

H.R.5351, Office of Intellectual Property and Competition Policy Act of 2004, entire bill.

S.2192, Cooperative Research and Technology Enhancement (CREATE) Act of 2004, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Page _____

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code DEF (one per page)

16. Specific Lobbying issues

, ,

***, no specific bill, biobased purchasing policy.

H.R.4454, Ecoterrorism Prevention Act of 2004, biothreat countermeasures.

H.R.4613, Department of Defense Appropriations Act, 2005, biothreat countermeasures.

S.15, Biodefense Improvement and Treatment for America Act, biothreat countermeasures.

S.2559, Department of Defense Appropriations Act, 2005, biothreat countermeasures.

S.666, Biological, Chemical, and Radiological Weapons Countermeasures Research Act, biothreat countermeasures.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None**HHS****House of Representatives****Senate****The White House**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Printed Name and Title Celeste Dembowski - Office Administrator Page

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENG (one per page)

16. Specific Lobbying issues

****, no specific bill, bioenergy legislation.

H.R.1644 , Energy Policy Act of 2003, entire bill.

H.R.4503, Energy Policy Act of 2004, entire bill.

H.R.6 , To enhance energy conservation and research and development, to provide for security and diversity i energy supply for the American people, and for other purposes, entire bill.

S.1005 , Energy Policy Act of 2003, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Page _____

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

****, no specific issue, FDA review practices.

***, no specific bill, NIH conflict of interest.

**, no specific bill, Clinical Trial Information Disclosure.

*, no specific bill, Bayh-Dole March-in Rights.

++++, no specific bill, Pharmacogenomics.

+++ , no specific bill, cell, gene and tissue therapy.

++ , no specific bill, PDUFA Implementation.

H.R.4531, Ronald Reagan Memorial Stem Cell Research Act of 2004, entire bill.

H.R.4682, Stem Cell Research Enhancement Act of 2004, entire bill.

H.R.4812, Stem Cell Discovery Through Diversity Act, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Page

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Client Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

***, no specific bill, MMA implementation.

+++; no specific bill, off-label studies.

H.R.5144, Cancer Care Preservation Act of 2004, entire bill.

S.2667, Medicare Replacement Drug Demonstration Project Improvement Act of 2004, entire bill.

S.2714, Medicare Prescription Drug Price Reduction Act of 2004, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 4/10/2005

Printed Name and Title Celeste Dembowski - Office Administrator Pag

Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

******, no specific bills, FDA issues including: Post Marketing Surveillance, Clinical Trials, Drug Reviews, Drug Manufacturing, and Counterfeiting.

++, no specific bill, implementation of the Prescription Drug User Fee Act.

H.R.4151, Brian Lykins Human Tissue Transplant Safety Act of 2004, entire bill.

H.R.4790, Drug Importation Promotion and Safety Act, entire bill.

H.R.4923, Safe IMPORT Act of 2004

Safe Importation of Medical Products and Other Rx Therapies Act of 2004, entire bill.

H.R.5155, Free Market Drug Act, entire bill.

H.R.5278, Community Pharmacy Preservation Act of 2004, entire bill.

S.2652, Medicare Prescription Drug Savings and Choice Act of 2004, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Page _____

Grant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)
16. Specific Lobbying issues
H.R.4656, Nanomanufacturing Investment Act of 2004, entire bill.

17. House(s) of Congress and Federal agencies contacted
Department of Health & Human Services
House of Representatives
Senate
White House

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	
Tarplin, Linda E.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator Page

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SMB (one per page)

16. Specific Lobbying issues

H.R.4149, To amend the Small Business Act to permit business concerns that are owned by venture capital companies or pension plans to participate in the Small Business Innovation Research Program, SBIR.

H.R.5108, Small Business Reauthorization and Manufacturing Assistance Act of 2004, SBIR.

S.2384, A bill to amend the Small Business Act to permit business concerns that are owned by venture capital companies or pension plans to participate in the Small Business Innovation Research Program, SBIR.

S.2821, Small Business Reauthorization and Manufacturing Assistance Act of 2004, SBIR.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate

The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title Celeste Dembowski - Office Administrator F

Grant Name: The OB-C Group, LLCClient Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R.1308 , Tax Relief, Simplification, and Equity Act of 2003, entire bill.

H.R.1372, Broad-Based Stock Option Plan Transparency Act of 2003, entire bill.

H.R.2896, American Jobs Creation Act of 2003, entire bill.

H.R.2931 , Orphan Drug Tax Credit Act of 2003, entire bill.

H.R.2968 , Biotechnology Future Investment Expansion Act of 2003 , entire bill.

H.R.3574, Stock Option Accounting Reform Act, entire bill.

H.R.4520, American Jobs Creation Act of 2004, entire bill.

H.RES.725, Providing for consideration of the bill (H.R. 3574) to require the mandatory expensing of stock of entire bill.

S.1773 , Biotechnology Future Investment Expansion Act of 2003, entire bill.

S.3019, Tax Technical Corrections Act of 2004, entire bill.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

HHS

House of Representatives

Senate


White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Johnson, Michael S.	
Keating, Thomas J.	
Marsh, Robert H.	Special Asst to the President for Leg. Affairs
Mellody, Charles J.	
Nelson, Patricia A.	
O'Brien, III, Lawrence F.	
Ruhlen, Mary Ellen	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature  Date 11/20/2022
Printed Name and Title Celeste Dembowski - Office Administrator Page

Client Name: The OB-C Group, LLC

Client Name: Biotechnology Industry Organization

Item	Description	Data
18a	Lobbyist Name	Tarplin, Linda E.
18b	Covered Official Position	
18c	New Lobbyist	No

